Somatostatin (SST) is a 28-amino-acid cyclic neuropeptide mainly secreted by neurons and endocrine cells. A major interest for SST receptors (SSTR) as target for in vivo diagnostic and therapeutic purposes was born since a series of stable synthetic SST-analouges PET became available, being the native somatostatin non feasible for clinical use due to the very low metabolic stability. The rationale for the employment of SST-analogues to image cancer is both based on the expression of SSTR by tumor and on the high affinity of these compounds for SSTR. The primary indication of SST-analogues imaging is for neuroendocrine tumors (NETs), which usually express a high density of SSTR, so they can be effectively targeted and visualized with radiolabeled SST-analogues in vivo. Particularly, SST-analogues imaging has been widely employed in gastroenteropancreatic (GEP) NETs. Nevertheless, a variety of tumors other than NETs expresses SSTR thus SST-analogues imaging can also be used in these tumors, particularly if treatment with radiolabeled therapeutic SST-analouges PET is being considered. The aim of this paper is to provide a concise overview of the role of positron emission tomography/computed tomography (PET/CT) with 68Ga-radiolabeled SST-analouges PET in tumors other than GEP-NETs.
1. Introduction
Scintigraphy with radiolabeled somatostatin (SST) analogues, first labeled with 123I and subsequently with 111In and Tc99m, has proven useful in diagnosing SST-receptor- (SSTR-) positive tumors with a reported detection rate of 50–100% [1–12]. Although SSTR scintigraphy shows high efficacy for whole-body imaging, there are some limitations in organs with higher physiological uptake (e.g., liver) and in terms of detection of small lesions due to the suboptimal physical resolution of the isotopes used [13, 14]. More recently, the development of SST-analogues radiolabeled with 68Ga for positron emission tomography (PET) imaging such as [68Ga-DOTA0-Tyr3]octreotide (68Ga-DOTATOC, 68Ga-edotreotide), [68Ga-DOTA0-1NaI3]octreotide (68Ga-DOTANOC), and [68Ga-DOTA0-Tyr3]octreotate (68Ga-DOTATATE) has brought clear advantages compared to radiolabeled SST-analogues scintigraphy offering a higher spatial resolution and improving pharmacokinetics [15–17]. Although 68Ga-DOTATOC, 68Ga-DOTANOC, and 68Ga-DOTATATE can all bind to SSTR subtype 2, they have different affinity profiles for the other SSTR subtypes [18]. In particular, 68Ga-DOTANOC also shows a good affinity for SSTR subtypes 3 and 5, 68Ga-DOTATOC also binds to SSTR5 (although with lower affinity than DOTANOC), while 68Ga-DOTATATE has a predominant affinity for SSTR2 [19]. More recently, has been evaluated the 68Ga-labeled DOTA-lanreotide (DOTALAN) for which has been reported a high affinity to the SSTR subtypes 2–5 [20, 21] although other data confirmed a high affinity only for SSTR subtypes 3 and 5 [22]. The dosimetric data measured for the whole body and for specific organs using 68Ga-DOTATATE [23] have been published recently. Although the organ doses and effective doses for 68Ga-DOTATATE, and 68Ga-DOTATOC are similar (though 68Ga-DOTATOC is slightly lower), the reported dosimetry of 68Ga-DOTANOC is the lowest [23–25]. Importantly, the effective dose per megabecquerel for 68Ga-labeled SST-analogues is approximately 3–5 times lower than for 111In-DTPA-octreotide resulting in an additional advantage of PET tracers compared to radiolabeled SST-analogues scintigraphy [23, 26].
Finally, there was no observed toxicity, immediate or delayed, during the followup (1 year), for 68Ga-DOTATATE demonstrating that this radiopharmaceutical is safe and both organ-specific and effective dose exposures are acceptable [23].
The primary indication of radiolabeled SST-analogues imaging is for neuroendocrine tumors (NETs), a heterogeneous group of neoplasms that arise from endocrine cells within glands (adrenal medulla, pituitary, and parathyroid) or from endocrine islets in thyroid, pancreas, or respiratory/gastrointestinal tract, which usually express a high density of SSTR. However radiolabeled SST-analogues can also be used in the imaging of inflammatory granulomatous and autoimmune conditions as well as non NETs although they cannot be considered as the first-choice functional imaging modality in the management of these patients, except for the determination of SSTR status [27–30]. Table 1 summarizes the different SSTR subtypes expressed by each tumor considered.
Somatostatin receptor subtypes expression in different tumors.
SSTR subtypes expression
References
Astrocytoma
SSTR1, SSTR2, and SSTR3 in variable percentages
[89]
Breast cancer
All of the five SSTR subtypes (predominantly SSTR2)
[90]
Colorectal cancer
Predominantly SSTR1 followed by SSTR5 and SSTR2
[91]
DTC
All of the five SSTR subtypes (predominantly SSTR2 and SSTR3)
[92]
Ependymoma
Commonly SSTR1 or SSTR5
[92]
Gastric carcinoma
Commonly SSTR2 and SSTR5, although SSTR3 is detected in several cases
[93]
GBM
Mainly SSTR3 followed by SSTR2 and SSTR1
[89]
GEP-NET
Predominantly SSTR1 and SSTR2 although SSTR5 is also often detected
[94]
GIST
All of the five SSTR subtypes in variable percentages
[95, 96]
HCC
Mainly SSTR5, although SSTR1, SSTR2, and SSTR3 are also often detected
[97]
Lymphoma
Mainly SSTR2 and SSTR3
[98]
Medulloblastoma
Mainly SSTR2
[94]
Melanoma
All of the five SSTR subtypes (predominantly SSTR1)
[99]
Meningioma
All of the five SSTR subtypes (predominantly SSTR1 and SSTR2)
[100]
Merkel cell carcinoma
Mainly SSTR2
[101]
MTC
All of the five SSTR subtypes (predominantly SSTR 2 and SSTR5)
[102, 103]
Neuroblastoma
Mainly SSTR2
[94]
NSCLC
Mainly SSTR2 and SSTR5 and, at lower level, SSTR3
[104]
Paraganglioma
Predominantly SSTR2 and SSTR1
[94]
PCa
All of the five SSTR subtypes (predominantly SSTR1)
[105, 106]
Phaeochromocytoma
Predominantly SSTR2 and SSTR1
[94]
Pituitary adenoma
Typical pattern of SSTR expression according to the secreting cells from which they originate:
[107–112]
GH secreting: mostly SSTR2 and SSTR5, often together
ACTH secreting: predominantly SSTR2 together with SSTR5
PRL secreting: predominantly SSTR1 and SSTR5
TSH secreting: SSTR2 is mainly coexpressed with SSTR3 and SSTR5
Clinically non-functioning: SSTR3 is highly expressed, followed by SSTR2 and, at lower level, SSTR5
The aim of this paper is to provide a concise overview of the role of positron emission tomography/computed tomography (PET/CT) with 68Ga-labeled SST-analogues in tumors other than GEP-NETs (Tables 2 and 3).
Overview of the role of positron emission tomography and positron emission tomography/computed tomography with 68Ga-radiolabeled somatostatin analogues in tumors other than gastroenteropancreatic neuroendocrine tumors.
Paraganglioma (n=3); bronchial carcinoid (n=6); prostate NET (n=1)
68Ga-DOTATOC PET
Staging/follow-up
Overall sensitivity = 97%*
Fanti et al. 2008 [31]
Paraganglioma (n=3); prostate NET (n=3); lymphoma (n=1)
68Ga-DOTANOC PET/CT
Restaging/treatment planning
Positive in 4/7 cases
Ambrosini et al. 2010 [48]
Paraganglioma (n=5); lung carcinoid (n=44); Merkel cell carcinoma (n=1); prostate NET (n=2); melanoma (n=1); thymic cancer (n=1)
68Ga-DOTANOC PET/CT
Bone mts detection
Overall sensitivity = 100%*
Haug et al. 2010 [50]
Paraganglioma (n=1); lung NET (n=4)
68Ga-DOTATATE PET/CT
Outcome prediction
Decreased 68Ga-DOTATATE uptake in tumor after the first cycle ofPRRT predicted time to progression and correlated with an improvement in clinical symptoms
*Overall results (no specific results for each tumor type).
Summary of the role of positron emission tomography and positron emission tomography/computed tomography with 68Ga-radiolabeled somatostatin analogues in tumors other than gastroenteropancreatic neuroendocrine tumors.
Tumor type
References
Publications (n=)
Patients (n=)
68Ga-somatostatin-analogues PET or PET/CT purpose
Future perspective*
Diagnosis/staging
PRRT selection
Other
Sympathoadrenal system tumors
Paraganglioma
[31–33, 37, 38, 40, 41, 48, 50, 67]
10
∑53
x
x
++
Phaechromocytoma
[32–37, 39]
7
∑38
x
x
x
++
Lung tumors
Carcinoid
[40–50, 66, 67]
13
∑140
x
x
++
NSCLC
[43, 51]
2
∑10
x
x
+/−
SCLC
[43, 47, 52]
3
∑32
x
x
+
Brain tumors
Neuroepithelial tumor
[32, 36, 53–55]
5
∑45
x
x
x
+/−
Meningioma
[53, 55–63]
9
∑301
x
x
++
Thyroid cancers
MTC
[33, 40, 47, 64–67]
7
∑48
x
x
++
DTC
[32, 68–70, 80]
5
∑72
x
x
++
Merkel cell carcinoma
[48, 67, 74–77]
6
∑7
x
x
x
+/−
Colorectal cancer
[80, 81]
2
∑2
x
+/−
Breast cancer
[78]
1
2
x
+/−
Prostate cancer
[31, 41, 48, 49, 83–85]
7
∑29
x
+/−
Melanoma
[48, 82]
2
∑19
x
+/−
Thymic cancer
[40, 48, 66, 67, 71–73]
8
∑51
x
x
−
Mesenchymal tumor
[32, 39, 86–88]
5
∑18
x
+
Lymphoma
[31, 80]
2
∑2
x
−
PET: positron emission tomography; PET/CT: positron emission tomography/computed tomography; PRRT: peptide radioreceptor therapy; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; MTC: medullary thyroid cancer; DTC: differentiated thyroid cancer. *Based on literature data we classified the use of radiolabeled somatostatin-analogues PET or PET/CT as ++: suitable; +: promising; +/−: undetermined; and −: not indicated.
2. Sympathoadrenal System Tumors
The use of 68Ga-labeled SST-analogues PET and PET/CT paraganglioma (Figure 1) and phaeochromocytoma (Figure 2) remains small, consisting mainly of case reports and small series.
68Ga-DOTATOC PET/CT images (MIP, sagittal, axial) in a patient with metastatic paraganglioma.
68Ga-DOTATOC PET/CT images (MIP, axial) in a patient affected by metastatic phaeocromochytoma.
Fanti et al. [31] evaluated the role of 68Ga-DOTANOC in 14 patients with NET including 3 cases of paragangliomas. All paragangliomas were detected with 68Ga-DOTANOC and were strongly positive. Mittal et al. [32] retrospectively evaluated 145 patients including phaeochromocytoma (n=2) and paraganglioma (n=3) with 68Ga-DOTATATE PET/CT. PET/CT was positive in only 1 patient affected by paraganglioma. Several authors have reported the higher diagnostic performances of 68Ga-DOTATATE PET/CT compared to 123I-MIBG scintigraphy in phaeochromocytoma and paraganglioma [33–35]. Kroiss et al. [36] reported a higher sensitivity for lesion detection of 68Ga-DOTATOC PET/CT in metastatic phaeochromocytoma patients (n=6) compared to 123I-MIBG scan (92% and 63%, resp.). More recently, Maurice et al. [37] reported similar results in 15 patients with phaeochromocytoma (n=9) or paragangliomas (n=6) evaluated with 68Ga-DOTATATE PET/CT and 123I-MIBG single photon emission computed tomography (SPECT). Utilizing 123I-MIBG scintigraphy as gold standard, 68Ga-DOTATATE had a sensitivity of 80% and a positive predictive value of 62%. The greatest discordance was in head and neck lesions, with the lesions in 4 patients being picked up by 68Ga-DOTATATE and missed by 123I-MIBG. On a per-lesion analysis, 68Ga-DOTATATE was superior to 123I-MIBG in detecting lesions in all anatomical locations (particularly bone lesions). Very recently, Sharma et al. [38] studied 26 patients with known or suspected head and neck paragangliomas by 68Ga-DOTANOC PET/CT and compared PET/CT findings to 123I-MIBG scintigraphy and CT/MRI results. 68Ga-DOTANOC PET/CT was positive in all patients and it was able to detect more lesions (n=78) compared to 123I-MIBG alone or combined with CT/MRI (n=30 and n=53, resp.). 68Ga-DOTANOC PET/CT has also been compared to CT for the evaluation of bone metastases in patients with NET including patients with paraganglioma (n=5), being more accurate than CT for the early identification of bone lesions [31].
Hofman et al. [39] compared 68Ga-DOTATATE PET/CT to 111In-octreotide imaging (SPECT or SPECT/CT) in a series of oncological patients including phaeochromocytoma (n=4) in order to identify the management impact of incremental diagnostic information obtained from PET/CT compared with conventional staging. 68Ga-DOTATATE PET/CT provided additional diagnostic information in a large proportion of patients with consequent high management impact. This impact included directing patients to curative surgery by identifying the primary site and directing patients with multiple metastases to systemic therapy.
In conclusion, in case of negative 123I-MIBG scan in patients with a high pretest probability of phaeochromocytoma or paraganglioma, 68Ga-labeled SST-analogues PET or PET/CT should be considered as the next investigation. Additionally, 68Ga-labeled SST-analogues PET/CT should be considered in the staging of patients in whom metastatic spread, particularly to the bone, is suspected.
3. Lung Tumors
68Ga-SST-analogues PET and PET/CT have been evaluated in all types of lung tumor (Figures 3 and 4). Hofmann et al. [15] compared the diagnostic values of 111In-octreotide scintigraphy and 68Ga-DOTATOC PET to morphologic imaging in 8 patients with metastatic carcinoid tumors including 2 bronchial carcinoids. 68Ga-DOTATOC PET was superior to 111In-octreotide scintigraphy in the identification of tumor lesions (overall sensitivity of 100% versus 85%). Similarly, Koukouraki et al. [40] used 68Ga-DOTATOC PET to evaluate 15 cases of carcinoid tumors, including 2 cases of pulmonary carcinoids, reporting an overall sensitivity of 92%. Gabriel et al. [41] used 68Ga-DOTATOC PET to evaluate 84 patients with NET, including 5 patients with bronchial carcinoids, and reported results higher than those obtained with radiolabeled SST-analogues SPECT or CT. Ambrosini et al. [42] compared 68Ga-DOTANOC PET/CT to CT scan in 11 patients with bronchial carcinoids. There were no false-positive findings at PET/CT, and 68Ga-DOTANOC PET/CT detected more lesions than CT (37 versus 21). On a clinical basis, 68Ga-DOTANOC PET/CT provided additional information in 82% of patients changing the clinical management in 33% of cases. Kayani et al. [43] compared the performance of 68Ga-DOTATATE PET/CT to [18F]FDG-PET/CT in the detection of pulmonary NET and correlated the PET radiotracer uptake to tumor grade on histology (11 typical carcinoids, 2 atypical carcinoids, 1 large cell neuroendocrine tumor, 1 small cell neuroendocrine carcinoma, 1 non-small cell lung cancer with neuroendocrine differentiation, and 2 cases of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia). All typical carcinoids showed high 68Ga-DOTATATE uptake (SUVmax≥8.2), but 4/11 showed negative or faint [18F]FDG uptake (SUVmax=1.7–2.9), while atypical carcinoids showed high uptake of [18F]FDG (SUVmax≥11.7), but 3/5 showed only faint accumulation of 68Ga-DOTATATE (SUVmax=2.2–2.8). Neither case of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia showed 68Ga-DOTATATE or [18F]FDG uptake. No false-positive results were observed on 68Ga-DOTATATE PET/CT, while [18F]FDG-PET/CT was false-positive in 3 cases due to inflammation. Kumar et al. [44] compared 68Ga-DOTATATE and [18F]FDG PET/CT in 7 patients with bronchial mass detected by CT (carcinoid tumors, n=3; inflammatory myofibroblastic tumor, n=1; mucoepidermoid carcinoma, n=1; hamartoma, n=1; synovial cell sarcoma, n=1). The typical carcinoids had mild [18F]FDG uptake and high 68Ga-DOTATOC uptake. Atypical carcinoid had moderate [18F]FDG uptake and high 68Ga-DOTATOC uptake. Inflammatory myofibroblastic tumor and mucoepidermoid carcinoma were positive on [18F]FDG-PET/CT (high and moderate uptake, resp.) and both were negative using 68Ga-DOTATOC PET/CT. Hamartoma showed no uptake on either [18F]FDG or 68Ga-DOTATOC PET/CT scans. Synovial cell sarcoma showed moderate [18F]FDG uptake and mild focal 68Ga-DOTATOC uptake. More recently, Jindal et al. [45] reported similar results in 20 patients with pulmonary carcinoids (13 typical and 7 atypical). In this series all the atypical carcinoids revealed higher uptake on the [18F]FDG-PET/CT than that in typical carcinoids while SUVmax was significantly higher in typical carcinoids (SUVmax=8.8–66) compared with atypical carcinoids (SUVmax=1.1–18.5) on 68Ga-DOTATOC PET/CT. Jindal et al. [46] in a retrospective analysis of patients with primary pulmonary carcinoid (n=20) who underwent 68Ga-DOTATOC PET/CT reported a detection rate of 95%. Putzer et al. [47] compared 68Ga-DOTALAN to 68Ga-DOTATOC PET in 53 patients with cancer including NET of the lung (n=4), SCLC (n=7), and bronchial carcinoid (n=3). Results showed that 68Ga-DOTATOC has a clear advantage over 68Ga-DOTALAN in detection and staging of this series of NETs.
68Ga-DOTATATE PET/CT images (MIP, axial) in a case of metastatic atypical lung carcinoid.
68Ga-DOTATOC PET/CT images (MIP, sagittal) in a patient with metastatic small cell lung carcinoma.
68Ga-SST-analogues PET/CT has also been compared to CT and bone scintigraphy for the evaluation of bone metastases in patients with lung NET being more accurate than CT and bone scintigraphy for the early identification of bone lesions [48, 49]. Finally, 68Ga-DOTATATE PET/CT has also been evaluated to predict progression-free survival and clinical outcome after peptide radioreceptor therapy (PRRT) in a series of patients with well-differentiated NET including 4 cases with lung NET. Results showed that patients with a decline in tumor-to-spleen SUV ratio (SUVT/S) after finishing the first cycle of PRRT had a significant longer time to progression than patients without favorable SUVT/S changes, suggesting that this parameter has a potential role in the early prediction of outcome in patients with well-differentiated NET [50].
Dimitrakopoulou-Strauss et al. [51] compared SSTR expression assessed by 68Ga-DOTATOC PET to tumor viability assessed by [18F]FDG-PET in 9 patients with NSCLC. Moderately enhanced 68Ga-DOTATOC uptake was noted in 7/9 primary tumors (mean SUVmax=2.018 for 68Ga-DOTATOC and 5.683 for [18F]FDG) but none of the 8 metastases which were positive on [18F]FDG-PET showed any 68Ga-DOTATOC uptake. These findings suggest a loss of the SSTR expression in metastases as compared with the NSCLC primary tumors.
Recently, we evaluated the performances of PET/CT with 68Ga-labeled SST-analogues in 24 patients with progressive extensive SCLC, to select patients for subsequent PRRT and compared 68Ga-labeled SST-analogues PET/CT results to contrast-enhanced CT findings. PET/CT was positive in 83% of patients and concordant to CT findings for all the sites of disease in 37.5% of cases [52].
In conclusion, the degree of uptake and different uptake patterns on [18F]FDG and 68Ga-SST-analogues PET or PET/CT may be helpful in differentiating between typical and atypical carcinoids. 68Ga-SST-analogues PET/CT may be useful also to stage disease in lung cancer and to select patients for the best treatment option, including PRRT.
4. Brain Neuroepithelial Tissue Tumors
The overexpression of SSTR has been reported in most high grade gliomas and it may be an interesting target for PRRT. 68Ga-DOTATOC PET showed SSTR expression (unpublished data from Innsbruck Medical University) in the majority of patients with brain tumors (89%) including glioma (n=3), medulloblastoma (n=2), anaplastic astrocytoma (n=1), and glioblastoma (n=13) with a different degree of radiotracer uptake (faint = 37%, medium = 21%, and intense = 31%) [53]. Mittal et al. [32] retrospectively evaluated 145 patients including neuroblastoma (n=8) with 68Ga-DOTATATE PET/CT with different purposes (initial staging, n=6; disease recurrence detection and response evaluation, n=1 each). In all the patients evaluated PET/CT was positive and in 5/6 cases in which 68Ga-DOTATATE PET/CT was performed as initial stage it was able to detect metastatic site of disease. Kroiss et al. [36] compared 68Ga-DOTATOC PET/CT to 123I-MIBG scan in a series of patients including neuroblastoma (n=5) reporting the superiority of PET/CT compared to scintigraphy (sensitivity of 97% and 91%, resp.). 68Ga-radiolabeled SST-analogues PET/CT has been also used to select patients for PRRT (neuroblastoma, n=8; glioma, n=3) [54, 55] and to evaluate treatment response combined with other imaging modalities [54].
5. Meningioma
Several authors have investigated the role of 68Ga-labeled SST-analogues PET/CT in patients with intracranial meningioma. Virtually, all patients with meningioma present 68Ga-labeled SST-analogues uptake (Figure 5). Afshar-Oromieh et al. [56] compared diagnostic accuracy of 68Ga-DOTATOC PET/CT to brain contrast-enhanced MRI in a large series of meningioma patients before radiotherapy. In the 134 patients investigated by both modalities, 190 meningiomas were detected by 68Ga-DOTATOC PET/CT and 171 by contrast-enhanced MRI. With the knowledge of the PET/CT data, MRI scans were reinvestigated, leading to the detection of 4 of the 19 incidental meningiomas, resulting in an overall detection rate of 92% of the meningioma lesions that have been found by PET/CT. Milker-Zabel et al. [57] compared the planning target volume outlined on CT and contrast-enhanced MRI to the planning target volume outlined on 68Ga-DOTATOC PET. Patients were treated according to the planning target volume defined with CT, MRI, and PET. The planning target volume defined with CT, MRI, and PET was somewhat larger than the volume detectable in MRI/CT (median 57.2 cc and 49.6 cc, resp.). In all patients 68Ga-DOTATOC PET delivered additional information concerning tumor extension and the planning target volume was significantly modified based on 68Ga-DOTATOC PET data in 73% of the cases. Similarly, Gehler et al. [58] defined the gross tumor volume by MRI, CT, and 68Ga-DOTATOC PET/CT in 26 patients with meningioma. Initial gross tumor volume definition was only based on radiological data and was secondarily integrated with 68Ga-DOTATOC PET/CT information. 68Ga-DOTATOC PET/CT provided additional information concerning tumor extension in 65% of patients (especially for skull base manifestations and recurrent disease after surgery) and modified the planning target volume in more than half of patients. Nyuyki et al. [59] investigated the potential value of 68Ga-DOTATOC PET/CT in the definition of the gross tumor volume in 42 meningioma patients before radiotherapy. 68Ga-DOTATOC PET/CT findings were compared to CT and MRI. Results showed that 68Ga-DOTATOC PET/CT enabled delineation of SSTR-positive meningiomas and provided additional information compared to both CT and MRI regarding the planning of stereotactic radiotherapy (particularly for the detection of osseous infiltration). Additionally, in a subgroup of patients with multiple meningiomas, 68Ga-DOTATOC PET/CT was able to identify more lesions compared to CT or MRI (19 versus 10, resp.). Similarly, Graf et al. [60] retrospectively compared 68Ga-DOTATOC PET/CT to MRI and CT in the delineation of infracranial extension of skull base meningiomas in 16 patients subsequently treated with fractionated stereotactic radiotherapy. The mean infracranial volume delineable in PET was somewhat larger than the volume detectable in MRI/CT (10.1±10.6 cm3 and 8.4±7.9 cm3, resp.). However, authors have concluded that 68Ga-DOTATOC PET/CT may be useful for planning fractionated stereotactic radiation when used in addition to conventional imaging modalities often inconclusive in the skull base region. Henze et al. [61, 62] characterized meningioma with dynamic 68Ga-DOTATOC PET in order to evaluate kinetic parameters reporting a good correlation with MRI and CT findings and a significant difference of radiotracer uptake between meningioma and reference tissue (mean SUV = 10.5 and 1.3, resp.) suggesting a possible role of 68Ga-DOTATOC PET/CT in monitoring meningioma SSTR expression after radiotherapy. Recently, Hänscheid et al. [63] evaluated the predictive role of 68Ga-labeled SST-analogues PET to assess tumor radionuclide uptake in PRRT of meningioma. Results showed a strong correlation between SUVmax and PRRT radionuclide tumor retention in the voxels with the highest uptake suggesting a potential role of 68Ga-labeled SST-analogues PET to estimate the PRRT achievable dose. Therefore 68Ga-labeled SST-analogues PET/CT may provide additional information in patients with uncertain or equivocal results using MRI or could help to confirm a diagnosis of meningioma based on MRI or may help to confirm MRI-based diagnosis of meningioma in cases of biopsy limitations. Finally, 68Ga-labeled SST-analogues PET or PET/CT may be useful to delineate the target volume for fractionated stereotactic radiotherapy.
68Ga-DOTATATE PET/CT images (MIP, coronal, sagittal, and axial) in a patient with meningioma.
6. Medullary Thyroid Cancer
Although studies investigating larger and more homogeneous patient populations are needed to better elucidate the potential diagnostic role of new PET tracers for the assessment of recurrent medullary thyroid carcinoma (MTC), the preliminary published data seem to suggest that the diagnostic role of 68Ga-SST-analogues appears to be controversial (Figure 6). In fact, well-differentiated tumors show a variable and often low SSTR subtype cell expression. Of course, the evidence of a high uptake of 68Ga-labeled SST-analogues could be used to accurately define the tumor biology “map” and therefore may be potentially helpful in selecting the most appropriate therapeutic option. Conry et al. [64] compared the sensitivity of 68Ga-DOTATATE PET/CT to [18F]FDG-PET/CT in a series of 18 patients with recurrent MTC. Although the overall detection rate for both procedures was comparable (positive results in 72% and 77% of the cases for 68Ga-DOTATATE and [18F]FDG, resp.), on a region-based analysis [18F]FDG-PET identified more metastatic lesions than 68Ga-DOTATATE PET/CT (28 versus 23, resp.). Treglia et al. [65] retrospectively compared PET/CT with 68Ga-DOTATATE, [18F]FDG, and [18F]DOPA in 18 patients with residual/recurrent MTC suspected on the basis of elevated serum calcitonin levels. Results showed statistically different sensitivity values between [18F]DOPA and [18F]FDG-PET/CT (72% and 17%, resp.) and between [18F]DOPA and 68Ga-DOTATATE PET/CT (72% and 33%, resp.). Miederer et al. [66] compared a score of SSTR2 immunoistochemistry with the in vivo SUV of preoperative or prebiopsy 68Ga-DOTATOC PET/CT in a small series of patients including 2 patients with metastases from MTC. In these patients who were negative on immunohistochemistry PET/CT showed a moderate 68Ga-DOTATOC uptake (SUVmax=4.4 and 6.8). Koukouraki et al. [67] evaluating the pharmacokinetics of 68Ga-DOTATOC in series of patients with metastatic NET reported the lowest 68Ga-DOTATOC uptake in the patient with MTC. In another series of patients, including one case of MTC, Koukouraki et al. [40] compared 68Ga-DOTATOC to [18F]FDG PET results. In this case 68Ga-DOTATOC PET showed 50% of lesions evident at [18F]FDG-PET. Very recently, Putzer et al. [47] compared 68Ga-DOTALAN to 68Ga-DOTATOC PET in 53 patients with cancer including 8 patients with MTC. In this series of NETs 68Ga-DOTATOC PET showed a clear advantage over 68Ga-DOTALAN PET in both lesion detection and staging.
68Ga-DOTATATE PET/CT images (MIP, axial) in a patient affected by metastatic medullary thyroid carcinoma.
7. Differentiated Thyroid Carcinoma
Although papillary, follicular, and anaplastic thyroid cancers and also Hürthle-cell carcinomas do not belong to the group of traditional NET, 68Ga-SST-analogues PET and PET/CT may be positive in many patients (Figure 7) and could provide, especially in negative radioiodine cases, new therapeutic options. Mittal et al. [32] retrospectively evaluated 145 patients including differentiated thyroid carcinoma (DTC) patients presenting thyroglobulin-elevated negative iodine scan (n=5) with 68Ga-DOTATATE PET/CT. In all patients evaluated, PET/CT was positive (cervical nodes, n=3; remnant and cervical nodes, n=1; thyroid bed soft tissue nodule, n=1). Middendorp et al. [68] compared 68Ga-DOTATOC PET/CT to [18F]FDG-PET/CT in 17 patients with recurrent DTC. Both PET tracers consistently detected metastases in 12 patients. [18F]FDG-PET/CT has been reported more sensitive compared to 68Ga-DOTATOC PET/CT in the detection of radioiodine negative lesions (64% versus 31%) but not in radioiodine positive lesions (48% versus 46%). On a lesion-by-lesion basis, only 2% of lesions were visible using 68Ga-DOTATOC PET/CT. Gabriel et al. [69] reported the usefulness of 68Ga-SST analogues PET/CT to identify patients with thyroid cancer with radioiodine negative metastases (n=6) suitable for PRRT. Similarly, our group used 68Ga-DOTATOC PET/CT to select patients with radioiodine negative metastatic DTC (n=41) for PRRT [70].
68Ga-DOTATATE PET/CT images (MIP, axial) in a patient with metastatic iodine-negative differentiated thyroid carcinoma.
8. Thymic Malignancies
Few data are available about the role of 68Ga-SST-analogues PET in thymic malignancies [40, 48, 66, 67, 71–73].
Miederer et al. [66] compared a score of SSTR2 immunoistochemistry with the in vivo SUV of preoperative or pre-biopsy 68Ga-DOTATOC PET/CT in a small series of patients including one case of thymoma. In this patient who was negative on immunohistochemistry, PET/CT showed a faint 68Ga-DOTATOC uptake (SUVmax=2.5). Dutta et al. [72] investigated 3 patients with thymic carcinoid tumors by 68Ga-DOTATOC PET/CT but none of these tumors showed radiotracer uptake. Koukouraki et al. [40] compared 68Ga-DOTATOC PET to [18F]FDG-PET in a series of patients including one case of carcinoid of thymus in which the disease was correctly addressed by both PET radiotracers. We reported a series of 39 patients with metastatic thymic malignancies evaluated by 68Ga-SST-analogues PET/CT and [18F]FDG-PET/CT. 68Ga-SST-analogues PET/CT and [18F]FDG-PET/CT were concordant in 43% of cases (both positive in 36% of cases and both negative in 8% of patients); in 52% of patients [18F]FDG-PET/CT was positive and 68Ga-SST-analogues PET/CT was negative while in the remaining 5% of cases 68Ga-SST-analogues PET/CT was positive and [18F]FDG-PET/CT was negative. In a per-lesion analysis, all lesions shown by contrast enhanced CT scan, which was considered the gold standard, were detected in 20% and 43% of cases using 68Ga-SST-analogues and [18F]FDG, respectively; in the remaining cases we observed at least one measurable CT lesion without either 68Ga-SST-analogues or [18F]FDG uptake. In this series of thymic neoplasms at restaging a predominant [18F]FDG positivity was observed compared to 68Ga-SST-analogues at PET/CT suggesting a relative loss of SSTR expression during thymic malignancies progression and a subsequent increasing of biological aggressiveness [73] (Figure 8).
68Ga-DOTATATE PET/CT images (MIP, axial) in a patient with thymoma.
9. Merkel Cell Carcinoma
Merkel cell tumors are aggressive neoplasms that often metastasize and, despite therapy, the disease-related death rate is high. Ultrastructurally and immunocytochemically, the majority of these tumors have neuroendocrine characteristics. Establishing the extent of the disease may ensure an optimal choice of treatment for these tumors; however, due to the rarity of these tumors, few cases have been evaluated by 68Ga-labeled SST-analogues PET/CT. Nevertheless, available data showed the usefulness of 68Ga-labeled SST-analogues PET/CT to stage and restage patients with Merkel cell carcinoma, and also to identify patients suitable for PRRT and to evaluate treatment response [48, 67, 74–77].
10. Breast Cancer
In breast cancer differentiated tumors express more SSTR2 than undifferentiated ones, and estrogens positively affect SSTR2 expression; additionally, the research of new factors that could allow a more accurate prognosis of the existing disease and that could improve traditional treatment strategies remains critical [29]. However no sufficient data are available about the role of 68Ga-SST-analogues PET or PET/CT in this clinical setting (Figure 9). Elgeti et al. [78] retrospectively analyzed 68Ga-DOTATOC PET/CT performed for staging purpose in 33 women with NET. In 6/33 patients 68Ga-DOTATOC PET/CT revealed the presence of a breast lesion classified as suspected in 4/6 cases. In 2 cases the suspected breast lesion was diagnosed as NET metastases while in the remaining 2 cases it was diagnosed as primary breast cancer resulting in a change of therapeutic management. Primary breast cancer presented a lower 68Ga-DOTATOC uptake compared to concomitant abdominal NET lesions. In this small series of patients 68Ga-DOTATOC PET/CT not only improved NET staging but also increased the chance to detect SSTR-positive breast cancer. In the case of breast lesions, authors suggested further diagnostic characterization since the confirmation of a secondary tumor impact on therapeutic management of patients.
68Ga-DOTATOC PET/CT images (MIP, axial) in a patient with metastatic breast cancer.
11. Colorectal Cancer
Some data suggest that SSTR2 gene expression in colorectal cancer might be related to a more favorable outcome [79]. However no sufficient data are available about the role of 68Ga-SST-analogues PET/CT in this clinical setting [80, 81]. Desai et al. [81] reported the usefulness of molecular imaging using different PET radiotracers in order to understand NET biology and subsequently to determine the best treatment option. In this case a different tumor pattern of [18F]FDG and 68Ga-DOTATATE uptake was shown by PET examinations within the liver, resulting in synchronous colorectal cancer and pancreatic NET liver metastases.
12. Melanoma
Few cases have been reported in the literature about the role of 68Ga-labeled SST-analogues PET/CT in melanoma patients [48, 82].
Brogsitter et al. [82] compared 68Ga-DOTATOC PET/CT to [18F]FDG-PET/CT in 18 patients with metastatic melanoma. 68Ga-DOTATOC PET/CT was positive in 61% of the investigated patients; however, on a lesion-by-lesion basis, only 22% of [18F]FDG-positive metastases were seen with 68Ga-DOTATOC PET/CT. Further, 68Ga-DOTATOC uptake was only faint (mean SUVmax=3.1, range 1.2–4.2) compared to [18F]FDG (mean SUVmax=28.2, range 2.3–115). The exact impact of 68Ga-SST-analogues PET/CT on staging and management of melanoma patient remains to be determined.
13. Prostate Cancer
Few cases have been reported in the literature about the role of 68Ga-labeled SST-analogues PET/CT in prostate cancer patients [31, 41, 48, 49, 83–85]. Luboldt et al. [84] assessed SSTR expression in 20 patients with advanced prostate cancer to potentially guide SSTR-mediated therapies. On a side-by-side analysis only 30% of bone scintigraphy-positive metastases were seen with 68Ga-DOTATOC PET/CT. The authors concluded by suggesting further studies with different SST-analogues with a higher affinity for SSTR1 and SSTR4 (expressed by prostate cancer), not adequately addressed with DOTATOC. The only case reported in the literature using 68Ga-DOTATATE showed intense radiotracer uptake in bone metastases, confirming bone scan results and suggesting a potential role of 68Ga-DOTATATE PET/CT to guide SSTR-mediated therapies also in this clinical setting [85].
14. Mesenchymal Tumors
Despite the promising results only few cases have been reported in the literature about the use of 68Ga-labeled SST-analogues PET/CT to evaluate tumor-induced osteomalacia (phosphaturic mesenchymal tumors) [32, 39, 86–88]. In the two larger series of patients (n=6 and n=8, resp.) with suspicious tumor-induced osteomalacia, PET/CT demonstrated high 68Ga-DOTATATE uptake and localized the tumor in 75–100% of the cases evaluated [32, 88].
In this clinical setting 68Ga-DOTATATE PET/CT may represent the first step functional imaging to identify the site of disease but further studies are needed to confirm these preliminary results.
15. Lymphoma
The use of 68Ga-labeled SST-analogues PET/CT in lymphoma is limited to sporadic cases [31, 80] (Figure 10).
68Ga-DOTATATE PET/CT images (MIP, axial) in a patient with non-Hodgkin lymphoma.
16. Conclusion and General Remarks
The use of 68Ga-labeled SST-analogues PET/CT in phaeochromocytoma and paraganglioma remains small, consisting mainly of case reports and small series. The diagnostic accuracy of 68Ga-SST-analogues PET/CT is superior to 131I-MIBG; thus, in the case of negative 123I-MIBG scan in patients with a high pretest probability of phaeochromocytoma or paraganglioma, 68Ga-labeled SST-analogues PET/CT should be considered. Additionally, 68Ga-labeled SST-analogues PET/CT should be considered in the staging of patients in whom metastatic spread, particularly to the bone, is suspected.
Although limited experience exists in NCSCL and SCLC, 68Ga-SST-analogues PET or PET/CT has been evaluated in all types of lung tumor. Particularly, the degree of uptake and the different uptake patterns on [18F]FDG and 68Ga-SST-analogues PET or PET/CT may be helpful to differentiate typical from atypical carcinoids. 68Ga-SST-analogues PET/CT may be useful also to stage lung cancer (especially for the early identification of bone lesions) and to select patients for the best treatment option, including PRRT.
Some interesting studies on radiolabeled SST-analogues PET/CT in patients with brain neuroepithelial tumors (either for staging, treatment selection, or response evaluation) are reported in the literature.
68Ga-labeled SST-analogues PET/CT has been widely used in patients with intracranial meningioma. 68Ga-labeled SST-analogues PET/CT provides additional information in patients with uncertain or equivocal results at MRI and helps to confirm a diagnosis of meningioma based on MRI or to confirm MRI-based diagnosis of meningioma in cases of biopsy limitations. Finally, 68Ga-labeled SST-analogues PET or PET/CT may be useful to delineate the target volume for fractionated stereotactic radiotherapy.
Although studies investigating larger and more homogeneous patient populations are needed to better elucidate the potential diagnostic role of radiolabeled SST-analogues for the assessment of recurrent MTC, the preliminary published data suggest a controversial role of 68Ga-SST-analogues since well-differentiated tumors show a variable and often low SSTR subtype cell expression.
68Ga-SST-analogues PET and PET/CT were positive in many patients with DTC providing, especially in negative radioiodine cases, new therapeutic options as PRRT. However, further studies comparing 68Ga-SST-analogues to radioiodine scintigraphy and [18F]FDG-PET/CT in DTC are needed.
Limited disappointing experience exists regarding the role of 68Ga-SST-analogues PET/CT in patients with thymic malignancies. In thymic neoplasms a predominant [18F]FDG positivity has been observed compared to 68Ga-SST-analogues at PET/CT suggesting a relative loss of SSTR expression during thymic malignancy progression and subsequent increasing of biological aggressiveness.
Few but significant data are available about the role of 68Ga-labeled SST-analogues PET/CT in Merkel cell carcinoma. 68Ga-labeled SST-analogues PET/CT is useful to stage and restage patients, and also to select treatment for PRRT and to assess treatment response.
Although only few cases have been reported in the literature about the use of 68Ga-labeled SST-analogues PET/CT in tumor-induced osteomalacia, 68Ga-DOTATATE PET/CT may represent the first step functional imaging to identify mesenchymal tumors; however further studies are needed to confirm the promising preliminary results.
No sufficient data are available about the role of 68Ga-SST-analogues PET or PET/CT in melanoma and breast, colorectal, and prostate cancers. The use of 68Ga-labeled SST-analogues PET/CT in lymphoma is limited to sporadic cases with unfavorable results.
In conclusion, although these preliminary experiences suggest a possible role of 68Ga-SST-analogues PET or PET/CT in many non GEP-NETs tumors, further studies are needed to confirm these promising results.
Conflict of Interests
All the authors declare that they have no conflict of interests.
ReubiJ. C.Peptide receptors as molecular targets for cancer diagnosis and therapy20032443894272-s2.0-004285492710.1210/er.2002-0007ReubiJ. C.WaserB.Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting20033057817932-s2.0-0037907532BombardieriE.MaccauroM.De DeckereE.SavelliG.ChitiA.Nuclear medicine imaging of neuroendocrine tumours2001122S51S612-s2.0-0035167560OlsenJ. O.PozderacR. V.HinkleG.HillT.O'DorisioT. M.SchirmerW. J.EllisonE. C.O'DorisioM. S.Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (OctreoScan)19952532512612-s2.0-0029328546BrigantiV.SestiniR.OrlandoC.BerniniG.La CavaG.TamburiniA.RaggiC. C.SerioM.MaggiM.Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors1997312238523912-s2.0-0031418445ChitiA.BrigantiV.FantiS.MonettiN.MasiR.BombardieriE.Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours200044142492-s2.0-0034115734ChitiA.FantiS.SavelliG.RomeoA.BellanovaB.RodariM.Van GraafeilandB. J.MonettiN.BombardieriE.Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours19982510139614032-s2.0-003171815710.1007/s002590050314KrenningE. P.KwekkeboomD. J.BakkerW. H.BreemanW. A. P.KooijP. P. M.OeiH. Y.Van HagenM.PostemaP. T. E.De JongM.ReubiJ. C.VisserT. J.ReijsA. E. M.HoflandL. J.KoperJ. W.LambertsS. W. J.Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients19932087167312-s2.0-0027517429SeregniE.ChitiA.BombardieriE.Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results19982566396582-s2.0-003183385610.1007/s002590050267JamarF.FiasseR.LenersN.PauwelsS.Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management19953645425492-s2.0-0028914799LebtahiR.CadiotG.SardaL.DaouD.FaraggiM.PetegniefY.MignonM.Le GuludecD.Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors19973868538582-s2.0-0030970530BangardM.BéhéM.GuhlkeS.OtteR.BenderH.MaeckeH. R.BiersackH. J.Detection of somatostatin receptor-positive tumours using the new 99mC-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide20002766286372-s2.0-001314613810.1007/s002590050556KowalskiJ.HenzeM.SchuhmacherJ.MäckeH. R.HofmannM.HaberkornU.Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3- octreotidein comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors20035142482-s2.0-003756970710.1016/S1536-1632(03)00038-6BuchmannI.HenzeM.EngelbrechtS.EisenhutM.RunzA.SchäferM.SchillingT.HaufeS.HerrmannT.HaberkornU.Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours20073410161716262-s2.0-3474883527010.1007/s00259-007-0450-1HofmannM.MaeckeH.BörnerA. R.WeckesserE.SchöffskiP.OeiM. L.SchumacherJ.HenzeM.HeppelerA.MeyerG. J.KnappW. H.Biokinetics and imaging with the somatostatin receptor PET radioligand68Ga-DOTATOC: preliminary data20012812175117572-s2.0-003521473010.1007/s002590100639WildD.SchmittJ. S.GinjM.MäckeH. R.BernardB. F.KrenningE.De JongM.WengerS.ReubiJ.-C.DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals20033010133813472-s2.0-014199653310.1007/s00259-003-1255-5AmbrosiniV.CampanaD.BodeiL.NanniC.CastellucciP.AllegriV.MontiniG. C.TomassettiP.PaganelliG.FantiS.68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors20105156696732-s2.0-77952297471AntunesP.GinjM.ZhangH.WaserB.BaumR. P.ReubiJ. C.MaeckeH.Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?20073479829932-s2.0-3425034918810.1007/s00259-006-0317-xAmbrosiniV.CampanaD.TomassettiP.GrassettoG.RubelloD.FantiS.PET/CT with 68Gallium-DOTA-peptides in NET: an overview2011802e116e1192-s2.0-8005363418810.1016/j.ejrad.2010.07.022Smith-JonesP. M.BischofC.LeimerM.GludovaczD.AngelbergerP.PangerlT.Peck-RadosavljevicM.HamiltonG.KasererK.KoflerA.Schlagbauer-WadlH.TraubT.VirgoliniI.DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy199914011513651482-s2.0-0033303656VirgoliniI.SzilvasiI.KurtaranA.AngelbergerP.RadererM.HavlikE.VorbeckF.BischofC.LeimerM.DornerG.KletterK.NiederleB.ScheithauerW.Smith-JonesP.Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients19983911192819362-s2.0-0031742949ReubiJ. C.SchärJ.-C.WaserB.WengerS.HeppelerA.SchmittJ. S.MäckeH. R.Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use20002732732822-s2.0-0034033495WalkerR. C.SmithG. T.LiuE.MooreB.ClantonJ.StabinM.Measured human dosimetry of 68Ga-DOTATATE201354855860HartmannH.ZöphelK.FreudenbergR.OehmeL.AndreeffM.WunderlichG.EisenhoferG.KotzerkeJ.Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations20094852012072-s2.0-7035032923010.3413/nukmed-0214PettinatoC.SarnelliA.Di DonnaM.CivollaniS.NanniC.MontiniG.Di PierroD.FerrariM.MarengoM.BergaminiC.68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors200835172792-s2.0-3684904971010.1007/s00259-007-0587-yKrenningE. P.BakkerW. H.KooijP. P. M.BreemanW. A. P.OeiH. Y.De JongM.ReubiJ. C.VisserT. J.BrunsC.KwekkeboomD. J.ReijsA. E. M.Van HagenP. M.KoperJ. W.LambertsS. W. J.Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide19923356526582-s2.0-0026720422WarnerR. R. P.Enteroendocrine tumors other than carcinoid: a review of clinically significant advances20051286166816842-s2.0-1884445731210.1053/j.gastro.2005.03.078CasciniG. L.CuccurulloV.MansiL.The non tumour uptake of 111In-octreotide creates new clinical indications in benign diseases, but also in oncology201054124362-s2.0-77952510480SmithM. C.MaggiM.OrlandoC.Somatostatin receptors in non-endocrine tumours200436supplement 1S78S852-s2.0-244269918110.1016/j.dld.2003.11.019VirgoliniI.AmbrosiniV.BomanjiJ. B.BaumR. P.FantiS.GabrielM.PapathanasiouN. D.PepeG.OyenW.De CristoforoC.ChitiA.Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE201037200420102-s2.0-7795407560510.1007/s00259-010-1512-3FantiS.AmbrosiniV.TomassettiP.CastellucciP.MontiniG.AllegriV.GrassettoG.RubelloD.NanniC.FranchiR.Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET200862106676712-s2.0-5604908614910.1016/j.biopha.2008.01.010MittalB. R.AgrawalK.ShuklaJ.BhattacharyaA.SinghB.SoodA.BhansaliA.Ga-68 DOTATATE PET/CT in neuroendocrine tumors: initial experience20134716NajiM.ZhaoC.WelshS. J.MeadesR.WinZ.FerrareseA.TanT.RubelloD.Al-NahhasA.68Ga-DOTA-TATE PET vs.123I-MIBG in identifying malignant neural crest tumours20111347697752-s2.0-8005262703910.1007/s11307-010-0396-8WinZ.RahmanL.ToweyD.Al-NahhasA.68Ga-DOTATATE PET imaging in neuroectodermal tumours200633, article S190WinZ.Al-NahhasA.ToweyD.ToddJ. F.RubelloD.LewingtonV.GishenP.68Ga-DOTATATE PET in neuroectodermal tumours: first experience20072853593632-s2.0-3414709326510.1097/MNM.0b013e32808ea0b0KroissA.PutzerD.UprimnyC.DecristoforoC.GabrielM.SantnerW.KranewitterC.WarwitzB.WaitzD.KendlerD.VirgoliniI. J.Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine20113858658732-s2.0-7995371772110.1007/s00259-010-1720-xMauriceJ. B.TrokeR.WinZ.RamachandranR.Al-NahhasA.NajiM.DhilloW.MeeranK.GoldstoneA. P.MartinN. M.ToddJ. F.PalazzoF.TanT.A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma201239126612702-s2.0-8485989095310.1007/s00259-012-2119-7SharmaP.ThakarA.SumanK. C. S.DhullV. S.SinghH.NaswaN.ReddyR. M.KarunanithiS.KumarR.KumarR.MalhotraA.BalC.68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma201354841847HofmanM. S.KongG.NeelsO. C.EuP.HongE.HicksR. J.High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours201256140472-s2.0-8485727440710.1111/j.1754-9485.2011.02327.xKoukourakiS.StraussL. G.GeorgouliasV.EisenhutM.HaberkornU.Dimitrakopoulou-StraussA.Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy20063310111511222-s2.0-3374923700010.1007/s00259-006-0110-xGabrielM.DecristoforoC.KendlerD.DobrozemskyG.HeuteD.UprimnyC.KovacsP.Von GuggenbergE.BaleR.VirgoliniI. J.68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT20074845085182-s2.0-3424852982410.2967/jnumed.106.035667AmbrosiniV.CastellucciP.RubelloD.NanniC.MustoA.AllegriV.MontiniG. C.MattioliS.GrassettoG.Al-NahhasA.FranchiR.FantiS.68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid20093042812862-s2.0-6314918320710.1097/MNM.0b013e32832999c1KayaniI.ConryB. G.GrovesA. M.WinT.DicksonJ.CaplinM.BomanjiJ. B.A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors20095012192719322-s2.0-7334910216710.2967/jnumed.109.066639KumarA.JindalT.DuttaR.KumarR.Functional imaging in differentiating bronchial masses: an initial experience with a combination of 18F-FDG PET-CT scan and 68Ga DOTA-TOC PET-CT scan20092387457512-s2.0-7035020878110.1007/s12149-009-0302-0JindalT.KumarA.VenkitaramanB.MeenaM.KumarR.MalhotraA.DuttaR.Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids201111170752-s2.0-7996049357310.1102/1470-7330.2011.0010JindalT.KumarA.VenkitaramanB.DuttaR.KumarR.Role of 68Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids20102543863912-s2.0-7865098474610.3904/kjim.2010.25.4.386PutzerD.KroissA.WaitzD.GabrielM.Traub-WeidingerT.UprimnyC.von GuggenbergE.DecristoforoC.WarwitzB.WidmannG.VirgoliniI. J.Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide201340364372AmbrosiniV.NanniC.ZompatoriM.CampanaD.TomassettiP.CastellucciP.AllegriV.RubelloD.MontiniG.FranchiR.FantiS.68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours20103747227272-s2.0-7795209522210.1007/s00259-009-1349-9PutzerD.GabrielM.HenningerB.KendlerD.UprimnyC.DobrozemskyG.DecristoforoC.BaleR. J.JaschkeW.VirgoliniI. J.Bone metastases in patients with neuroendocrine tumor: 68Ga- DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy2009508121412212-s2.0-6824915474910.2967/jnumed.108.060236HaugA. R.AuernhammerC. J.WänglerB.SchmidtG. P.UebleisC.GökeB.CummingP.BartensteinP.TilingR.HackerM.68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors2010519134913562-s2.0-7795709610710.2967/jnumed.110.075002Dimitrakopoulou-StraussA.GeorgouliasV.EisenhutM.HerthF.KoukourakiS.MäcKeH. R.HaberkornU.StraussL. G.Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using 68Ga-DOTATOC PET and comparison with 18F-FDG PET20063378238302-s2.0-3374553939410.1007/s00259-005-0063-5SolliniM.FarioliD.FroioA.ChellaA.AstiM.BoniR.GrassiE.RoncaliM.VersariA.ErbaP. A.Brief report on the use of radiolabeled somatostatin analogs for the diagnosis and treatment of metastatic small-cell lung cancer patients2013810951101WaitzD.PutzerD.KostronH.VirgoliniI. J.Treatment of high-grade glioma with radiolabeled peptides20115532232292-s2.0-8295518217310.1016/j.ymeth.2011.09.004HeuteD.KostronH.Von GuggenbergE.IngorokvaS.GabrielM.DobrozemskyG.StockhammerG.VirgoliniI. J.Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC20105133974002-s2.0-7795035474610.2967/jnumed.109.072819GainsJ. E.BomanjiJ. B.FershtN. L.SullivanT.D'SouzaD.SullivanK. P.AldridgeM.WaddingtonW.GazeM. N.177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma2011527104110472-s2.0-7996031580010.2967/jnumed.110.085100Afshar-OromiehA.GieselF. L.LinhartH. G.HaberkornU.HaufeS.CombsS. E.PodlesekD.EisenhutM.KratochwilC.Detection of cranial meningiomas: comparison of Ga-DOTATOC PET/CT and contrast-enhanced MRI20123914091415Milker-ZabelS.Zabel-du BoisA.HenzeM.HuberP.Schulz-ErtnerD.HoessA.HaberkornU.DebusJ.Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET20066512222272-s2.0-3364600578910.1016/j.ijrobp.2005.12.006GehlerB.PaulsenF.ÖksüzM. T.HauserT.-K.EschmannS. M.BaresR.PfannenbergC.BambergM.BartensteinP.BelkaC.GanswindtU.[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning200941, article 562-s2.0-7154915467810.1186/1748-717X-4-56NyuykiF.PlotkinM.GrafR.MichelR.SteffenI.DeneckeT.GeworskiL.FahdtD.BrennerW.WurmR.Potential impact of 68Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas20103723103182-s2.0-7794927278910.1007/s00259-009-1270-2GrafR.PlotkinM.SteffenI. G.WurmR.WustP.BrennerW.BudachV.BadakhshiH.Magnetic resonance imaging, computed tomography, and 68Ga-DOTATOC positron emission tomography for imaging skull base meningiomas with infracranial extension treated with stereotactic radiotherapy—a case series201281, article 12-s2.0-8485528647110.1186/1746-160X-8-1HenzeM.SchuhmacherJ.HippP.KowalskiJ.BeckerD. W.DollJ.MäckeH. R.HofmannM.DebusJ.HaberkornU.PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-Octreotide: first results in patients with meningiomas2001427105310562-s2.0-0034949018HenzeM.Dimitrakopoulou-StraussA.Milker-ZabelS.SchuhmacherJ.StraussL. G.DollJ.MäckeH. R.EisenhutM.DebusJ.HaberkornU.Characterization of 68Ga-DOTA-D-Phe1-Tyr 3-octreotide kinetics in patients with meningiomas20054657637692-s2.0-20644465208HänscheidH.SweeneyR. A.FlentjeM.BuckA. K.LöhrM.SamnickS.KreisslM.VerburgF. A.PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma201239128412882-s2.0-8485989887610.1007/s00259-012-2124-xConryB. G.PapathanasiouN. D.PrakashV.KayaniI.CaplinM.MahmoodS.BomanjiJ. B.Comparison of 68Ga-DOTATATE and 18F- fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma201037149572-s2.0-7294910323610.1007/s00259-009-1204-zTregliaG.CastaldiP.VillaniM. F.PerottiG.de WaureC.FiliceA.AmbrosiniV.CremoniniN.SantimariaM.VersariA.FantiS.GiordanoA.RufiniV.Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma2012395695802-s2.0-8485526235710.1007/s00259-011-2031-6MiedererM.SeidlS.BuckA.ScheidhauerK.WesterH.-J.SchwaigerM.PerrenA.Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT200936148522-s2.0-5724909588010.1007/s00259-008-0944-5KoukourakiS.StraussL. G.GeorgouliasV.SchuhmacherJ.HaberkornU.KarkavitsasN.Dimitrakopoulou-StraussA.Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy20063344604662-s2.0-3364587862110.1007/s00259-005-0006-1MiddendorpM.SelkinskiI.HappelC.KranertW. T.GrünwaldF.Comparison of positron emission tomography with [18F]FDG and [68Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data201054176832-s2.0-77952508806GabrielM.AndergassenU.PutzerD.KroissA.WaitzD.Von GuggenbergE.KendlerD.VirgoliniI. J.Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients201054192992-s2.0-77952487451VersariA.SolliniM.FrasoldatiA.FraternaliA.FiliceA.FroioA.AstiM.FioroniF.CremoniniN.PutzerD.ErbaP. A.Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patientsThyroid. In pressVasamilietteJ.HohenbergerP.SchoenbergS.DiehlS.DinterD. J.MarxA.StroebelP.StraussL. G.Dimitrakopoulou-StraussA.Treatment monitoring with 18F-FDG PET in metastatic thymoma after 90Y-Dotatoc and selective internal radiation treatment (SIRT)20091232713092-s2.0-72249116467DuttaR.KumarA.JulkaP. K.MathurS. R.KaushalS.KumarR.JindalT.SuriV.Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation20101167327362-s2.0-7864961271310.1510/icvts.2010.237651FroioA.SolliniM.FraternaliA.RoncaliM.FarioliD.BoniR.ChellaA.CalabreseF.ErbaP. A.VersariA.Thymic neoplasms evaluation: role of 68Ga-peptide and [18F]FDG PET/CT2013545, supplement 1, article 1632SchneiderC.SchlaakM.BludauM.MarkiefkaB.SchmidtM. C.68Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma20123711081111SchmidtM. C.UhrhanK.MarkiefkaB.HasselbringL.SchlaakM.CremerB.KunzeS.BaumR. P.DietleinM.68Ga-DotaTATE PET-CT followed by Peptide Receptor Radiotherapy in combination with capecitabine in two patients with Merkel Cell Carcinoma20125363366SalavatiA.PrasadV.SchneiderC.-P.HerbstR.BaumR. P.Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology2012263653692-s2.0-8485721228810.1007/s12149-012-0578-3EpstudeM.TornquistK.RiklinC.di LenardoF.WinterhalderR.HugU.StrobelK.Comparison of, (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized merkel cell carcinoma201338283284ElgetiF.AmthauerH.DeneckeT.SteffenI.HeuckF.StelterL.RufJ.Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours20084762612652-s2.0-5734914941010.3413/nukmed-0185Casini RaggiC.CalabròA.RenziD.BrigantiV.CianchiF.MesseriniL.ValanzanoR.Cameron SmithM.CortesiniC.TonelliF.SerioM.MaggiM.OrlandoC.Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa2002824194272-s2.0-0036187843HaugA.Cindea-DrimusR.AuernhammerC.SchmidtG.BartensteinP.HackerM.68Ga-DOTATATE PET/CT in the diagnosis of recurrent neuroendocrine tumors201253supplement 1, article 419DesaiK.WatkinsJ.WoodwardN.QuigleyA. M.ToumpanakisC.BomanjiJ.CaplinM.Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin2011451e8e112-s2.0-7865093689510.1097/MCG.0b013e3181e04d3cBrogsitterC.ZöphelK.WunderlichG.KämmererE.SteinA.KotzerkeJ.Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma2013344749SouvatzoglouM.MaurerT.TreiberU.WeirichG.KrauseB. J.EsslerM.68Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases2009485N52N542-s2.0-77954579456LuboldtW.ZöphelK.WunderlichG.AbramyukA.LuboldtH.-J.KotzerkeJ.Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT201012178842-s2.0-7714912903610.1007/s11307-009-0230-3AlonsoO.GambiniJ. P.LagoG.GaudianoJ.QuagliataA.EnglerH.In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer20113611106310642-s2.0-84856258173Von FalckC.RodtT.RosenthalH.LängerF.GoeslingT.KnappW. H.GalanskiM.68Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia2008355, article 10342-s2.0-4214916102210.1007/s00259-008-0755-8WoffE.GarciaC.TantL.MuylleK.GhanemG.BourgeoisP.FlamenP.Imaging of tumour-induced osteomalacia using a gallium-68 labelled somatostatin analogue20102010bcr0220102750Clifton-BlighR. J.HofmanM. S.DuncanE.Sim IeWDarnellD.ClarksonA.WongT.WalshJ. P.GillA. J.EbelingP. R.HicksR. J.Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT201398687694MawrinC.SchulzS.PauliS. U.TreuheitT.DieteS.DietzmannK.FirschingR.SchulzS.HölltV.Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas200463113192-s2.0-0348050035KumarU.GrigorakisS. I.WattH. L.SasiR.SnellL.WatsonP.ChaudhariS.Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology20059221751862-s2.0-2164445089710.1007/s10549-005-2414-0QiuC.-Z.ZhuS.-Z.WuY.-Y.WangC.HuangZ.-X.QiuJ.-L.Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer20061213201120152-s2.0-33646444794Pazaitou-PanayiotouK.Tiensuu JansonE.KoletsaT.KotoulaV.StridsbergM.KarkavelasG.KarayannopoulouG.Somatostatin receptor expression in non-medullary thyroid carcinomas201211290296SzepeshaziK.SchallyA. V.NagyA.WagnerB. W.BajoA. M.HalmosG.Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas2003987140114102-s2.0-014167510710.1002/cncr.11649ReubiJ. C.WaserB.SchaerJ.-C.LaissueJ. A.Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands20012878368462-s2.0-003492461210.1007/s002590100541PalmieriG.MontellaL.AielloC.BarbieriF.Di VizioD.SchulzS.BeninatiS.BudillonA.CaragliaM.InsabatoL.FlorioT.Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract20073233954002-s2.0-3414713884310.1007/s00726-006-0386-yFlorioT.MontellaL.CorsaroA.De ChiaraA.ApiceG.FazioliF.LastoriaS.SchettiniG.PalmieriG.In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors2003233246524712-s2.0-0042807618BläkerM.SchmitzM.GochtA.BurghardtS.SchulzM.BröringD. C.PaceA.GretenH.De WeerthA.Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas20044111121182-s2.0-344288040810.1016/j.jhep.2004.03.018DalmV. A. S. H.HoflandL. J.MooyC. M.WaaijersM. A.Van KoetsveldP. M.LangerakA. W.StaalF. T. J.Van Der LelyA.-J.LambertsS. W. J.Van HagenM. P.Somatostatin receptors in malignant lymphomas: targets for radiotherapy?20044518162-s2.0-1842451625LumS. S.FletcherW. S.O'DorisioM. S.NanceR. W.PommierR. F.CapraraM.Distribution and functional significance of somatostatin receptors in malignant melanoma20012544074122-s2.0-003502310910.1007/s002680020102ArenaS.BarbieriF.ThellungS.PiraniP.CorsaroA.VillaV.DadatiP.DorcarattoA.LapertosaG.RavettiJ.-L.SpazianteR.SchettiniG.FlorioT.Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity2004661-21551662-s2.0-1074422012010.1023/B:NEON.0000013498.19981.55PapottiM.MacriL.PaganiA.AloiF.BussolatiG.Quantitation of somatostatin receptor type 2 in neuroendocrine (Merkel cell) carcinoma of the skin by competitive RT-PCR199910137462-s2.0-0032916392ZatelliM. C.TagliatiF.TaylorJ. E.RossiR.CullerM. D.Degli UbertiE. C.Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT2001865216121692-s2.0-003500000410.1210/jc.86.5.2161MatoE.Matías-GuiuX.ChicoA.WebbS. M.CabezasR.BernáL.De LeivaA.Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma1998837241724202-s2.0-003178457510.1210/jc.83.7.2417FeroneD.ArvigoM.SeminoC.JaquetP.SaveanuA.TaylorJ. E.MoreauJ.-P.CullerM. D.AlbertelliM.MinutoF.BarrecaA.Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation20052896E1044E10502-s2.0-3364466430010.1152/ajpendo.00209.2005DizeyiN.KonradL.BjartellA.WuH.GadaleanuV.HanssonJ.HelboeL.AbrahamssonP.-A.Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines20027391982-s2.0-003623719010.1016/S1078-1439(01)00173-9KosariF.MunzJ. M. A.Savci-HeijinkC. D.SpiroC.KleeE. W.KubeD. M.TillmansL.SlezakJ.KarnesR. J.ChevilleJ. C.VasmatzisG.Identification of prognostic biomarkers for prostate cancer2008146173417432-s2.0-4154909058810.1158/1078-0432.CCR-07-1494SaveanuA.JaquetP.Somatostatin-dopamine ligands in the treatment of pituitary adenomas200910283902-s2.0-6734916022410.1007/s11154-008-9086-0TatenoT.KatoM.TaniY.OyamaK.YamadaS.HirataY.Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas20095645795842-s2.0-6844908901810.1507/endocrj.K08E-186FuscoA.GunzG.JaquetP.DufourH.GermanettiA. L.GullerM. D.BarlierA.SaveanuA.Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas200815855956032-s2.0-4314909026110.1530/EJE-07-0806YoshiharaA.IsozakiO.HizukaN.NozoeY.HaradaC.OnoM.KawamataT.KuboO.HoriT.TakanoK.Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting longterm response to octreotide therapy20075411331382-s2.0-3394760575010.1507/endocrj.K06-133SaveanuA.Morange-RamosI.GunzG.DufourH.EnjalbertA.JaquetP.A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies2001145135412-s2.0-0034924296FlorioT.BarbieriF.SpazianteR.ZonaG.HoflandL. J.Van KoetsveldP. M.FeeldersR. A.StellaG. K.TheodoropoulouM.CullerM. D.DongJ.TaylorJ. E.MoreauJ.-P.SaveanuA.GunzG.DufourH.JaquetP.Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: A Multi-Center Study20081525835962-s2.0-4584912104210.1677/ERC-07-0271